Cagent Vascular specializes in advanced vascular technologies aimed at improving patient outcomes in the treatment of vascular diseases. The company focuses on developing innovative solutions that enhance the performance of vascular interventions, particularly through the use of bioresorbable materials. Their flagship product line includes stents and grafts designed to provide temporary support to blood vessels while promoting natural healing processes, ultimately leading to improved long-term results for patients.

The technology employed by Cagent Vascular is rooted in a deep understanding of vascular biology and materials science. Their products utilize proprietary bioresorbable polymers that gradually dissolve in the body, reducing the risk of long-term complications associated with permanent implants. This approach not only supports the vessel during the critical healing phase but also minimizes the need for additional surgical interventions, aligning with the company's commitment to advancing patient care through innovative and effective vascular solutions.

United States

Cagent Vascular (Wayne, PA) has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology

Cagent Vascular

Company Details